OCTIMET have now partnered OMO-1 and OMO-2 with Shanghai Allist Pharmaceuticals Co., Ltd. for Greater China and DeuterOncology NV for Rest of the World.
OMO-1 is an oral, highly selective small molecule MET kinase inhibitor, that has demonstrated potent single agent and combination activity in a range of preclinical cancer models.
OCTIMET have now partnered OMO-1 and OMO-2 with Shanghai Allist Pharmaceuticals Co., Ltd. for Greater China and DeuterOncology NV for Rest of the World.
OMO-1 is an oral, highly selective small molecule MET kinase inhibitor, that has demonstrated potent single agent and combination activity in a range of preclinical cancer models.
